cilofexor (GS-9674) / Gilead  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cilofexor (GS-9674) / Gilead
NCT02654002: Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

Completed
1
120
US
Cilofexor, GS-9674, Placebo
Gilead Sciences
Nonalcoholic Steatohepatitis (NASH)
07/16
07/16
NCT02808312: Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

Completed
1
57
US, RoW
Cilofexor, GS-9674
Gilead Sciences
Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
10/18
10/18
ACTRN12619000655145: A Phase 1 Open-Label, Parallel-Group, Two-Treatment, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9674 and GS-0976 in Subjects with Normal Renal Function and Severe Renal Impairment

Completed
1
20
 
Gilead Sciences Inc , Gilead Sciences Inc
Nonalcoholic Steatohepatitis (NASH), Renal impairment
 
 
NCT04060147: Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

Terminated
1
11
US
Cilofexor, CILO, GS-9674
Gilead Sciences
Primary Sclerosing Cholangitis, Compensated Cirrhosis
09/21
09/21

Download Options